0001104659-23-089331.txt : 20230809
0001104659-23-089331.hdr.sgml : 20230809
20230809163020
ACCESSION NUMBER: 0001104659-23-089331
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230807
FILED AS OF DATE: 20230809
DATE AS OF CHANGE: 20230809
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lee Jennifer Kayden
CENTRAL INDEX KEY: 0001801372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38223
FILM NUMBER: 231155654
MAIL ADDRESS:
STREET 1: C/O KRYSTAL BIOTECH, INC.
STREET 2: 2100 WHARTON STREET, SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
FORMER NAME:
FORMER CONFORMED NAME: Chien Jennifer
DATE OF NAME CHANGE: 20200128
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001649904
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462159271
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-264-4280
MAIL ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: RHYTHM METABOLIC, INC.
DATE OF NAME CHANGE: 20150803
4
1
tm2323302-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-08-07
0
0001649904
RHYTHM PHARMACEUTICALS, INC.
RYTM
0001801372
Lee Jennifer Kayden
222 BERKELEY STREET, 12TH FLOOR
BOSTON
MA
02116
0
1
0
0
EVP, Head of North America
1
Common Stock
2023-08-07
4
M
0
8591
6.80
A
14517
D
Common Stock
2023-08-07
4
S
0
11223
24.1778
D
3294
D
Common Stock
2023-08-09
4
M
0
1718
6.80
A
5012
D
Common Stock
2023-08-09
4
S
0
1718
24.66
D
3294
D
Stock Option (Right to Buy)
6.80
2023-08-07
4
M
0
8591
0
D
2032-02-08
Common Stock
8591
73909
D
Stock Option (Right to Buy)
6.80
2023-08-09
4
M
0
1718
0
D
2032-02-08
Common Stock
1718
72191
D
Includes 986 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2023.
The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023.
The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
/s/ Hunter Smith, Attorney-in-Fact for Jennifer Lee
2023-08-09